Provided by Tiger Trade Technology Pte. Ltd.

Mirum Pharmaceuticals, Inc.

93.90
-2.8500-2.95%
Post-market: 93.900.00000.00%19:30 EDT
Volume:948.71K
Turnover:89.37M
Market Cap:6.10B
PE:-6.67
High:97.57
Open:97.57
Low:93.57
Close:96.75
52wk High:130.00
52wk Low:63.23
Shares:64.93M
Float Shares:56.42M
Volume Ratio:1.77
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.0800
EPS(LYR):-0.4700
ROE:-702.97%
ROA:-6.79%
PB:-585.03
PE(LYR):-199.79

Loading ...

Mirum Pharmaceuticals Initiated at Buy by Citigroup

Dow Jones
·
Jun 02

Mirum Pharmaceuticals Inc : Citigroup Initiates Coverage With Buy Rating; Price Target $145

THOMSON REUTERS
·
Jun 02

Mirum Pharmaceuticals initiated with a Buy at Citi

TIPRANKS
·
Jun 02

Mirum announces new data from its rare liver disease programs at EASL

TIPRANKS
·
May 31

Mirum Pharmaceuticals Announces New Data From Rare Liver Disease Programs Presented at the Easl International Liver Congress 2026

THOMSON REUTERS
·
May 31

Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Fate Therapeutics (FATE) and Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
May 27

H.C. Wainwright Reaffirms Their Buy Rating on Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
May 22

Mirum presents late-breaking Phase 2b VISTAS volixibat data in PSC pruritus at EASL 2026

Reuters
·
May 21

U.S. RESEARCH ROUNDUP-CAVA Group, Eagle Materials, Vertiv

Reuters
·
May 20

Mirum Pharmaceuticals Initiated at Outperform by Wolfe Research

Dow Jones
·
May 19

Mirum Pharmaceuticals initiated with an Outperform at Wolfe Research

TIPRANKS
·
May 19

Mirum director Saira Ramasastry disposes of common shares worth $218,940

Reuters
·
May 19

Mirum plans USD 600 million convertible senior notes offering due 2032

Reuters
·
May 19

What Mirum Pharmaceuticals (MIRM)'s Volixibat PSC Trial Win and $600M Notes Deal Means For Shareholders

Simply Wall St.
·
May 18

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 15

Stock Track | Mirum Pharmaceuticals Soars 5.26% Intraday on Favorable Debt Offering and Positive Drug Trial Results

Stock Track
·
May 13

BRIEF-Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering

Reuters
·
May 13

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes

THOMSON REUTERS
·
May 13

Mirum Pharmaceuticals announces $600M convertible senior notes offering

TIPRANKS
·
May 13

Mirum Pharmaceuticals Plans Offering of Senior Notes due 2032

MT Newswires Live
·
May 13